![Xavier Matias-Guiu Guia](/media/upload/cache/129949_a115x115.jpg)
Xavier Matias-Guiu Guia
Degree: PhD
973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/C-3039-2009
Groups
Publications
-
Croner RS; Geppert CI; Bader FG; Nitsche U; Späth C; Rosenberg R; Zettl A; Matias-Guiu X; Tarragona J; Güller U; Stürzl M; Zuber M
Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
BRITISH JOURNAL OF CANCER 110 2544-2550. .
-
Espinosa, I; Catasus, L; D' Angelo E; Mozos, A; Pedrola, N; Bertolo, C; Ferrer, I; Zannoni, GF; West, RB; van de Rijn, M; Matias-Guiu, X; Prat, J
Stromal signatures in endometrioid endometrial carcinomas
Modern Pathology 27 631-639. .
-
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
MOLECULAR CANCER THERAPEUTICS 13 776-787. .
-
Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X
Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
PLOS ONE 9 -. .
-
Maiques O; Santacana M; Valls J; Pallares J; Mirantes C; Gatius S; García Dios DA; Amant F; Pedersen HC; Dolcet X; Matias-Guiu X
Optimal protocol for PTEN immunostaining; role of analytical and preanalyticat variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues
HUMAN PATHOLOGY 45 522-532. .
-
García-Carbonero R; Vilardell F; Jiménez-Fonseca P; González-Campora R; González E; Cuatrecasas M; Capdevila J; Aranda I; Barriuso J; Matías-Guiu X
Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
CLINICAL & TRANSLATIONAL ONCOLOGY 16 243-256. .
-
Matias-Guiu X; Davidson B
Prognostic biomarkers in endometrial and ovarian carcinoma
VIRCHOWS ARCHIV 464 315-331. .
-
Matias-Guiu X; De Lellis R
Medullary Thyroid Carcinoma: a 25-Year Perspective
ENDOCRINE PATHOLOGY 25 21-29. .
-
Santacana, M; Maiques, O; Valls, J; Gatius, S; Lopez-Garcia, MA; Palacios, J; Dolcet, X; Matias-Guiu, X
Immunohistochemical Profiling in Assessing Histological Type in Endometrial Carcinoma
Modern Pathology 27 304-304. .
-
Bergada, L; Santacana, M; Garcia, V; Carceller, JA; Dolcet, X; Matias-Guiu, X
Role of Y-H2AX Expression in Prediction of Radiation Resistance in Endometrial Carcinoma
LABORATORY INVESTIGATION 94 276-276. .
-
Macià A; Vaquero M; Gou-Fàbregas M; Castelblanco E; Valdivielso JM; Anerillas C; Mauricio D; Matias-Guiu X; Ribera J; Encinas M
Sprouty1 induces a senescence-associated secretory phenotype by regulating NFjB activity: implications for tumorigenesis
CELL DEATH AND DIFFERENTIATION 21 333-343. .
-
Veà, A.; Barrera, J.; Velasco, A.; Casanova, J.M.; Matias-Guiu, X.; Martí, R.M.
Utilidad de la siascopia en el diagnóstico de lesiones melanocíticas
Piel 29 654-659. .
Projects
- Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
- EPH Receptor Signaling in Endometrial Cancer
- Ajuts per a la contractació de personal investigador novell (FI)
- Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
- "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
- EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
- Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
- Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
- CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
- DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
- Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
- VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU